A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus

Lupus

Volumn 7, Issue 2, 1998, Pages 80-85

  Tsakonas, E ^a   Joseph, L ^a   Esdaile, J M ^b   Choquette, D ^c   Senecal J L ^c   Cividino, A ^d   Danoff, D ^a   Osterland, C K ^e   Yeadon, C ^e   Smith, C D ^f  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c NOTRE DAME HOSPITAL   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e ROYAL VICTORIA HOSPITAL   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Hydroxychloroquine; Major flare; Nephritis; Systemic lupus erythematosus; Vasculitis

Indexed keywords

ANTIMALARIAL AGENT; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG WITHDRAWAL; FEMALE; GLOMERULONEPHRITIS; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

ADULT; ANTIMALARIALS; AZATHIOPRINE; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 6844255888     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120398678919778     Document Type: Article

References (22)

1. The Canadian Hydroxychloroquine Study Group. A randomized trial of the effect of withdrawing hydroxychloroquine sulphate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150-154.
2. Rudnicki RD, Gresham GE, Rothfield NF. The efficacy of antimalarials in systemic lupus erythematosus. J Rheumatol 1975; 2: 323-330.
3. Dubois EL. Antimalarials in the management of discoid and systemic lupus erythematosus. Semin Arthritis Rheum 1978; 8: 33-51.
4. Ziff M, Esserman P, McEwan C. Observations on the course and treatment of systemic lupus erythematosus. Arthritis Rheum 1958; 1: 332-350.
5. Fox RI, Kang H-I. Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation. Lupus 1993; 2(Suppl 1): S9-S12.
6. Sperber K et al. Selective regulation of cytokine secretion by hydroxychloroquine: Inhibition of IL-1 and IL-6 by monocytes and T-cells. J Rheumatol 1993; 20: 803-808.
7. Wallace DJ et al. The effect of hydroxychloroquine therapy on soluble accessory factors and cytokines in systemic lupus erythematosus. J Rheumatol 1994; 2: 375-376.
8. Wallace DJ: Antimalarial drugs In: Wallace DJ, Hahn BH (eds). Dubois' Lupus Erythematosus (4th edn). Philadelphia, Lea 573.
9. Wallace DJ. Antimalarials agents and lupus Rheum Dis Clin North Am 1994; 20: 243-263.
10. Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
11. Borenstein M. The case for confidence intervals in controlled trials. Controlled Clin Trials 1994; 15: 411-428.
12. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
13. Cox DR. Regression models and life tables. J R Stat Soc (series B) 1972; 34: 187-220
14. Meenan RF, Gertman PM, Mason JH. Measuring health status in arthritis: the arthritis impact measurement scales. Arthritis Rheum 1989; 23: 146-152.
15. Urowitz MB, Gladman DD, Tozman EC, Goldsmith CH. The lupus activity criteria count (LACC). J Rheumatol 1984; 11: 783-787
16. Bombardier C et al. and the committee on prognosis studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 1630-1640.
17. Meinão IM et al. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus 1996; 5: 237-241.
18. Feinstein AR. Clinical Epidemiology. The Architecture of Clinical Research WB Saunders Co., Philadelphia, 1985.
19. Swaak et al Systemic lupus erythematosus II. Observations on the occurrence of exacerbations in the disease course: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 1989; 48: 455-460.
20. Petri M, Genovese M. Incidence of 5 risk factors for hospitalizations in systemic lupus erythematosus: a prospective study of the Hopkins lupus cohort. J Rheumatol 1992; 19: 1559-1565.
21. Clarke AE et al A Canadian study of the total medical care costs for patients with systemic lupus erythematosus and the predictors of costs. Arthritis Rheum 1993; 36: 1548-1559.
22. McInnes PM et al. The economic impact of treatment of severe lupus nephritis with prednisone and intravenous cyclophosphamide Arthritis Rheum 1994; 37: 1000-1006.